Buradasınız

Anasayfa » Content

OSTEOSARKOMLU HASTALARDA METHOTREXATE DÜZEYLERİNİN DEĞERLENDİRİLMESİ

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2001

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The evaluation methotrexate levels in osteosarkoma patients. Our study aims to evaluate the plasma MTX levels in 25 patients with osteosarcoma diagnosis and receiving high doses of MTX (12 g/m2). The MTX levels of the individuals included in this study, 267 samples with osteosarcoma of the extremity, were tested by EMIT (Behring) from september 1997 to jun 2000. The MTX levels were evaluated by statistical and the results were like this 12. hours 314,28 ± 138,47 pmol, 24. hours 68,52 ± 51,32 pmol, 42. hours 10,25 ± 8,62 pmol, 48. hours 5,81 + 9,49 pmol, 72. hours 0,42 + 0,34 pmol. When the relationship of these results with the necrosis ratio is evaluated by Fischer's chi-square test statistically, the results were not found to be significant as for 12 hours; p=0.30 %95 (Ci=0.60-11.62), for 24. hours; p=0.77 %95 (Cİ=0.259-2.584).
Bookmark/Search this post with
Abstract (Original Language): 
Çalışmamızda Tıbbi Biyoloji Anabilim Dalı, Methotrexate ölçüm laboratuvannda Eylül 1997 ile Haziran 2000 tarihleri arasında takipleri yapılan, osteosarkom tanısı konmuş, 12 g /m2 yüksek doz Methotrexate uygulanan 25 hastanın, plazma Methotrexate düzeylerini değerlendirmeyi amaçladık. Çalışmaya dahil olan hastaların Methotrexate düzeyleri, spesifik ölçüm yöntemlerinden birisi olan EMİT(Enzyme -multiplied immunoassay technique) Behring yöntemi kullanılarak test edildi. Laboratuvanmızda ölçümlerini gerçekleştirdiğimiz 92 Methotrexate tedavisinin farklı saatlerde alınıp gönderilen toplam 267 Methotrexate plazma düzeyi istatistiksel olarak değerlendirildiğinde; 12.saatte 314,28 ± 138,47 pmol/lt, 24.saatte 68,52 ± 51,32 pmol/lt, 42.saatte 10,25 ± 8,62 umol/lt, 48.saatte 5.81 ± 9.49 umol/lt ve 72,saatte 0.42 ± 0.34 umol/lt olarak bulunmuştur. Sonuçların nekroz oranı ile ilişkisi, Fisher'in chi-square testi ile istatistiksel olarak değerlendirildiğinde 12. saatte; p=0.30 %95 (Ci=0.60-11.62), 24. saatte; p=0.77 %95 (Ci=0.259-2.584) olarak bulunmuş ve anlamlılık görülmemiştir.
FULL TEXT (PDF): 
PDF icon arastirmax-osteosarkomlu-hastalarda-methotrexate-duzeylerinin-degerlendirilmesi.pdf
  • 1-2
59-65
  • Turkish

REFERENCES

References: 

1. Bacci G, Ferrari S, Delepine N, Pertoni F, Picci P, Mercu-ri M, Baccini P, Brach del Prever A, Tienghi A, Comman-done A, Campanacci M:Predictive Factors of histologic
response to primary chemothrapy in osteosarcoma of the extremity:Study of 272 patient preoperatively treated with high-dose methotrexate doxorubicin, and cisplatin.J Clin Oncol,16:658 (1998).
2. Crom WR, Taylor RH, Pratt CB: Methotrexate Therapeu-tic use and serum con centration monitoring Syva Com-pany 1990 Revised August 1992.
3. Luyckx M, Cazin JL, Brunet C, GosselinP, Demaille MC: Clinical pharmacokinetics of 6-hours infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses.Eur J Clin Pharmacol, 28:457 (1985).
4. Meyer WH, Loftin SK, Houghton JA, Houghton PJ: Ac-cumulation, intracellular metabolism, and antitumor acti-vity of high-and low-dose methotrexate in human osteosarcoma xenografts.Cancer Commun, 2(6):219, (1990).
5. Provisor A.J, Ettinger LJ, Nacheman JB, Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES, Kisker CT, Miser RS: Treatment of nonmetastatic Krailo-osteosarcoma of extremity with preoperative and postope-rative chemoterapy: A report from the children's cancer group. J Clin Oncol, 15:76, (1997).
6. Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE: Patients characteristics associated with high-risk methotrexate concentrations and toxicity J Clin Oncol, Aug;12(8)1667 (1994).
7. Treon SP, Chabner BA: Concepts in use of high-dose met-hotrexate therapy. Clinical Chemistry 42:8(B) 1322, (1996).

Thank you for copying data from http://www.arastirmax.com